Related Experiment Video

Updated: Sep 27, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews

Salmaan Kanji1,2, Sydney Morin3, Kyla Agtarap4

  • 1The Ottawa Hospital, 501 Smyth Rd, Ottawa, ON, K1H 8L6, Canada. skanji@toh.ca.

Drugs
|April 13, 2022
PubMed
Abstract

Insights

Immune checkpoint inhibitor (ICI) adverse events (AEs) like fatigue and diarrhea are common. Early recognition and multidisciplinary management of these AEs are crucial for better cancer patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacovigilance

Background:

  • Immune checkpoint inhibitors (ICIs) are vital cancer therapies.
  • Effective management of ICI-associated adverse events (AEs) requires interdisciplinary expertise.
  • Increased awareness of potential AEs can improve patient outcomes.

Purpose of the Study:

  • To synthesize evidence on the incidence and severity of AEs from systematic reviews of ICI therapies.
  • To consolidate data on AEs across various cancer types treated with ICIs.

Main Methods:

  • Systematic literature search of four databases for relevant systematic reviews.
  • Inclusion of reviews reporting AE incidence, severity (CTCAE grading), and eligibility criteria.
  • Data extraction of PICOTTS elements and quality assessment using AMSTAR-2.

Main Results:

  • 129 systematic reviews were included, reporting on over 76 AEs.
  • Fatigue, diarrhea, and rash were the most common all-grade AEs.
  • High-grade diarrhea, colitis, and neutropenia were the most frequent severe AEs. Combination therapies often showed higher AE incidence.

Conclusions:

  • Recognition and management of ICI-related AEs necessitate broad specialist involvement beyond oncologists.
  • Enhanced awareness of AEs can lead to earlier detection and improved patient management.
  • Further research is needed on rare AEs and those in specific cancer subtypes.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

583
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
691
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
3.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
186
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.2K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
74.6K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.5K